226 related articles for article (PubMed ID: 29955134)
1. Characterisation of tumour microvessel density during progression of high-grade serous ovarian cancer: clinico-pathological impact (an OCTIPS Consortium study).
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Nuti M; Taube ET; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Br J Cancer; 2018 Aug; 119(3):330-338. PubMed ID: 29955134
[TBL] [Abstract][Full Text] [Related]
2. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium.
Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI
Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846
[TBL] [Abstract][Full Text] [Related]
3. [Prognostic value of microvessel density and angiogenesis-related molecules in epithelial ovarian cancer].
Tan XJ; Lang JH; Lou WZ; Shen K; Xu XY
Zhonghua Zhong Liu Za Zhi; 2008 Apr; 30(4):274-8. PubMed ID: 18788631
[TBL] [Abstract][Full Text] [Related]
4. Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancer.
Patel JN; Braicu I; Timms KM; Solimeno C; Tshiaba P; Reid J; Lanchbury JS; Darb-Esfahani S; Ganapathi MK; Sehouli J; Ganapathi RN
Br J Cancer; 2018 Oct; 119(9):1060-1066. PubMed ID: 30318511
[TBL] [Abstract][Full Text] [Related]
5. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study.
Rubatt JM; Darcy KM; Hutson A; Bean SM; Havrilesky LJ; Grace LA; Berchuck A; Secord AA
Gynecol Oncol; 2009 Mar; 112(3):469-74. PubMed ID: 19135712
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma.
Siamakpour-Reihani S; Owzar K; Jiang C; Turner T; Deng Y; Bean SM; Horton JK; Berchuck A; Marks JR; Dewhirst MW; Alvarez Secord A
Gynecol Oncol; 2015 Oct; 139(1):23-9. PubMed ID: 26260910
[TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor receptor 2 (VEGFR2) correlates with long-term survival in patients with advanced high-grade serous ovarian cancer (HGSOC): a study from the Tumor Bank Ovarian Cancer (TOC) Consortium.
Guan J; Darb-Esfahani S; Richter R; Taube ET; Ruscito I; Mahner S; Woelber L; Prieske K; Concin N; Vergote I; Van Nieuwenhuysen E; Achimas-Cadariu P; Glajzer J; Woopen H; Stanske M; Kulbe H; Denkert C; Sehouli J; Braicu EI
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1063-1073. PubMed ID: 30810838
[TBL] [Abstract][Full Text] [Related]
8. Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.
Pinto MP; Balmaceda C; Bravo ML; Kato S; Villarroel A; Owen GI; Roa JC; Cuello MA; Ibañez C
Gynecol Oncol; 2018 Oct; 151(1):10-17. PubMed ID: 30078505
[TBL] [Abstract][Full Text] [Related]
9. Expression of a novel endothelial marker, C-type lectin 14A, in epithelial ovarian cancer and its prognostic significance.
Krishna Priya S; Kumar K; Hiran KR; Bindhu MR; Nagare RP; Vijaykumar DK; Ganesan TS
Int J Clin Oncol; 2017 Feb; 22(1):107-117. PubMed ID: 27567920
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of ICAM-1 Predicts Poor Survival in High-Grade Serous Ovarian Carcinoma: A Study Based on TCGA and GEO Databases and Tissue Microarray.
Wang S; Yin C; Zhang Y; Zhang L; Tao L; Liang W; Pang L; Fu R; Ding Y; Li F; Jia W
Biomed Res Int; 2019; 2019():2867372. PubMed ID: 31312656
[TBL] [Abstract][Full Text] [Related]
11. Ovarian serous carcinoma: relationship of p53 and bcl-2 with tumor angiogenesis and VEGF expression.
Crasta JA; Mishra S; Vallikad E
Int J Gynecol Pathol; 2011 Nov; 30(6):521-6. PubMed ID: 21979585
[TBL] [Abstract][Full Text] [Related]
12. Does the degree of intratumoural microvessel density and VEGF expression have prognostic significance in osteosarcoma?
Ek ET; Ojaimi J; Kitagawa Y; Choong PF
Oncol Rep; 2006 Jul; 16(1):17-23. PubMed ID: 16786118
[TBL] [Abstract][Full Text] [Related]
13. BRCA mutational status, initial disease presentation, and clinical outcome in high-grade serous advanced ovarian cancer: a multicenter study.
Petrillo M; Marchetti C; De Leo R; Musella A; Capoluongo E; Paris I; Benedetti Panici P; Scambia G; Fagotti A
Am J Obstet Gynecol; 2017 Sep; 217(3):334.e1-334.e9. PubMed ID: 28549976
[TBL] [Abstract][Full Text] [Related]
14. Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.
Czekierdowski A; Czekierdowska S; Danilos J; Czuba B; Sodowski K; Sodowska H; Szymanski M; Kotarski J
J Physiol Pharmacol; 2008 Sep; 59 Suppl 4():53-65. PubMed ID: 18955754
[TBL] [Abstract][Full Text] [Related]
15. The associations between serum VEGF, bFGF and endoglin levels with microvessel density and expression of proangiogenic factors in malignant and benign ovarian tumors.
Szubert S; Moszynski R; Michalak S; Nowicki M; Sajdak S; Szpurek D
Microvasc Res; 2016 Sep; 107():91-6. PubMed ID: 27312585
[TBL] [Abstract][Full Text] [Related]
16. Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer.
Stanske M; Wienert S; Castillo-Tong DC; Kreuzinger C; Vergote I; Lambrechts S; Gabra H; Gourley C; Ganapathi RN; Kolaschinski I; Budczies J; Sehouli J; Ruscito I; Denkert C; Kulbe H; Schmitt W; Jöhrens K; Braicu I; Darb-Esfahani S
Neoplasia; 2018 Mar; 20(3):280-288. PubMed ID: 29466768
[TBL] [Abstract][Full Text] [Related]
17. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer.
Strickland KC; Howitt BE; Shukla SA; Rodig S; Ritterhouse LL; Liu JF; Garber JE; Chowdhury D; Wu CJ; D'Andrea AD; Matulonis UA; Konstantinopoulos PA
Oncotarget; 2016 Mar; 7(12):13587-98. PubMed ID: 26871470
[TBL] [Abstract][Full Text] [Related]
18. Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer.
Han ES; Burger RA; Darcy KM; Sill MW; Randall LM; Chase D; Parmakhtiar B; Monk BJ; Greer BE; Connelly P; Degeest K; Fruehauf JP
Gynecol Oncol; 2010 Dec; 119(3):484-90. PubMed ID: 20870280
[TBL] [Abstract][Full Text] [Related]
19. Effect of BRCA mutational status on survival outcome in advanced-stage high-grade serous ovarian cancer.
Kim SI; Lee M; Kim HS; Chung HH; Kim JW; Park NH; Song YS
J Ovarian Res; 2019 May; 12(1):40. PubMed ID: 31064392
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]